Advances of biomarkers in nasopharyngeal carcinoma’s early detection  

作　　者：Xiao-Hui Zheng Allan Hildesheim Wei-Hua Jia 

机构地区：[1]State Key Laboratory of Oncology in South China,Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy,Guangdong Provincial Clinical Research Center for Cancer,Sun Yat-sen University Cancer Center,Guangzhou 510060,China [2]Costa Rican Agency for Biomedical Investigation,INCIENSA Foundation,San Jose 10108,Costa Rica

出　　处：《Science Bulletin》2024年第2期141-145,共5页科学通报（英文版）

基　　金：supported by the National Key Research and Development Program of China(2021YFC2500400);the National Natural Science Foundation of China(81802708);the Key Area Research and Development Program of Guangdong Province,China(2019B110233004);the Science and Technology Planning Project of Guangdong Province,China(2019B030316031).

摘　　要：Nasopharyngeal carcinoma(NPC),a highly invasive and metastatic cancer,is widely prevalent in South China,Southeast Asia,and North Africa.NPC patients with stages I and II are often asymptomatic.Therefore,NPC patients are usually diagnosed with advanced-stage(stages III and IV)at their first visit.Detection of NPC at early stage is the key to improve the survival of patients.Epstein-Barr virus(EBV)plays an essential role in NPC occurrence in endemic areas.EBV-based biomarkers,including EBV antibody in serum and EBV DNA in plasma,have been specifically proposed for NPC early detection.Herein,we summarize recent advances in biomarkers for the early detection of NPC.

关 键 词：PATIENTS NASOPHARYNGEAL NASOPHARYNGEAL 

分 类 号：R739.63[医药卫生—肿瘤]